Core Viewpoint - Iwubio has demonstrated steady growth in its financial performance, with a focus on innovation in the desensitization treatment sector, positioning itself as a leader in a competitive market [1] Group 1: Financial Performance - For the year 2024, Iwubio reported a revenue of 925 million yuan, representing a year-on-year growth of 9.10% [1] - The net profit attributable to shareholders was 318 million yuan, an increase of 2.46% year-on-year [1] - In Q1 2025, the company achieved a revenue of 228 million yuan, up 5.7% year-on-year, with a net profit of 74 million yuan, reflecting a growth of 1.5% [1] - Operating cash flow for Q1 2025 reached 85.88 million yuan, marking a significant increase of 96.2% [1] - Cumulatively, the company has distributed over 850 million yuan in cash dividends since its listing, which is approximately four times the amount raised during its IPO [1] Group 2: Competitive Advantages - Iwubio has established three competitive barriers: technological innovation, product scarcity, and industry leadership [2][3][4] - The company invested 125 million yuan in R&D in 2024, accounting for 13.48% of its revenue, which is above the industry average [2] - Iwubio's product "Dust Mite Drops" is the only sublingual desensitization treatment available in China, providing a significant advantage in terms of safety and convenience compared to subcutaneous alternatives [3] - The market share of Iwubio's "Dust Mite Drops" has consistently remained above 81.72%, confirming its leading position in the domestic desensitization treatment market [4] Group 3: Growth Potential - The allergy treatment market is expected to grow due to the increasing prevalence of allergic diseases, with reports indicating that around 40% of the Chinese population suffers from such conditions [5] - Iwubio's "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" have shown significant growth, with the latter achieving a 76.43% increase in 2024 [5] - The company is expanding its product offerings in the allergy testing market, with new products like "Pollen Skin Prick Test Solutions" receiving market approval [5] - Iwubio is also venturing into stem cell therapies and natural medicines, aiming to create a second growth curve [6] - The company has identified a drug molecule for antibiotic-resistant tuberculosis and is advancing its clinical research [6] Group 4: Strategic Outlook - Iwubio's strategic positioning in the allergy treatment sector, combined with its innovative approaches in stem cell and natural medicine, suggests a robust growth trajectory [7] - The company is well-positioned to navigate the evolving pharmaceutical landscape, focusing on both maintaining its core allergy treatment business and exploring new therapeutic areas [7]

德岛大学医院开发的方法是将利用患者自己的干细胞制成的胰岛素生成细胞移植给患者，以补充 胰岛素。据悉移植后几乎不会出现排异反应，且不像iPS细胞那样需要进行基因导入，不易产生 基因错误…… 日本德岛大学医院的池本哲也教授等人3月24日表示，最早将于2025年夏季开始临床试验，利用从患者 自己的脂肪中提取的干细胞来治疗1型糖尿病。通过特殊方式将干细胞培养成胰岛素生成细胞，并将其 移植给患者，以期根治糖尿病。力争在2030年左右实现实用化。 1型糖尿病是一种因自身免疫反应导致降低血糖的胰岛素生成细胞受损的疾病，据推算日本国内有10万 ~14万患者。这种疾病多发于年轻人，与受生活习惯影响的2型糖尿病不同。患者可能出现失明及心肌 梗塞等并发症，需要自行注射胰岛素。 关于1型糖尿病的治疗，日本京都大学医院也计划2025年开始移植利用iPS细胞制成的分泌胰岛素的胰岛 细胞的临床试验，治疗方法的开发竞争日益激烈。 德岛大学医院的池本教授谈到自己团队开发的方法表示："由于是来自自己的细胞，移植后几乎不会出 现排异反应，且不像iPS细胞那样需要进行基因导入，因此不易产生基因错误，这是一大优势"。 版权声明：日本经济新闻社版权所有 ...

据IPO早知道消息，11月1日晚间，贝达药业（300558.SZ）发布公告，公司拟与杭州瑞普晨创科技 有限公司（下称"瑞普晨创"）签署《战略合作协议》，双方将合作开发干细胞治疗业务，在人多能 干细胞向胰岛细胞诱导分化技术领域展开深入合作。 同时，贝达药业拟出资2000万元投资瑞普晨创，投后占比0.9390%。贝达药业关联人贝橙创投拟出 资2000万元，投后占比0.9390%。瑞普晨创现股东，同为贝达关联人的宁波六谷出资500万元，投 后总占比10.3756%。 丁列明为瑞普晨创实控人。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 贝达药业表示，公司拟通过此次投资与合作布局糖尿病治疗市场，并逐步进军细胞和基因治疗的广阔 领域，符合公司发展战略。 此次投资为瑞普晨创A轮融资，由中国风投领投，除贝达药业及其关联人外，其他跟投方包括联想创 投、荷塘创投等。此轮融资总额超亿元。 瑞普晨创专注于干细胞再生技术创新，由贝达药业董事长及首席执行官丁列明博士于2014年联合创 立，由北京大学干细胞研究中心主任邓宏魁教授担任首席科学顾问。截止此公告披露日，丁列明直接 持有瑞普晨创46.80%出资额， ...